heritable disorders #{149} genetic analysis #{149} restriction fragment length polymorphism
With an estimated prevalence of 1 in 2500 [1] for CharcotMarie-Tooth (CMT) disease in general----70% being of the slow nerve conduction type 112], of which -70% are caused by duplications [3] -the overall prevalence of the CMT1A duplication should be -1 in 5000.#{176} Some of these patients are carriers of de novo mutations, which makes the underlying mechanism of this mutation an important mutagenic event in peripheral hereditary motor and sensory neuropathy. CMT1A was first mapped near the chromosome 17 centromeric region [4] and later localized to band l7pll.2-l2 [5] by linkage studies. A 1.5-Mb duplication in this region [6, 7] was found to be associated with the disease. This region contains PMP22, the gene for peripheral myelin protein 22 [8] [9] [10] [11] ; this gene is believed to play a role in Schwann cell proliferation and differentiation and to have a structural function [12] . The presence of three copies of the PMP22 gene in CMT1A suggests an overproduction of the protein, thus causing the CMT1A pathology. Unequal crossing-over at meiosis is thought to be the mechanism for this duplication [7] , which is mediated by repeated sequences of>17 kb known as CMT1A-REP flanking the duplicated region [13] . The reciprocal recombination product of this duplication is a deletion of the same length that provokes hereditary neuropathy with liability to pressure palsies (HNPP) [14] . CMT lA-REP sequences can be distinguished by EcoRI digestion, which produces a proximal 7.8-kb fragment and a distal 6.0-kb fragment [13] . Duplication and deletion generate different numbers of copies of these fragments [14] fragments an attractive approach for diagnoses of these disorders [15, 16] . EcoPJ digests were hybridized with the 1.8-kb EcoRl fragment from cosmid clone c20G2 [13] , which detects a 7.8-kb proximal and a 6.0-kb distal CMT1A-REP sequence. This 1.8-kb EcoRI fragment is also known as probe pNE 102 [16] . For some patients (Table 1) , a BamHl digest was hybridized with a full-length cDNA probe for PMP22 (pCD25).
MaterialsandMethods
Hybridization densities on autoradiographs were measured and compared by use of scanning apparatus and dosing software (Image MasterTM; Pharmacia Biotech, Uppsala, Sweden). All probes except cosmid clone c20G2 (obtained from J.R. Lupski, Houston, TX) were made available by the European CMT Consortium management (C. Van Broeckhoven, University of Antwerp, Belgium).
Results
RFLP probes pVAW4O9R3a, pEW4O1HE, and pVAW412HEc hybridize to loci in the duplicated (CMT1A) or deleted (HNPP) region and are routinely used for diagnostic purposes in this region. Dosage differences between alleles, or rarely the detection of three alleles (probe pVAW4O9R3a), indicate the presence of an extra allele in DNA of CMT1A patients. From our Of our patients, 67 showed concordance between results obtained with the RFLP probes from the duplicated/deleted region and the CMT1A-REP probe, and 9 revealed unusual ratios among their CMT lA-REP fragments (Fig. 1) . Two patients did not show dosage differences ( On the basis of these observations, Chance et al. proposed a model for an unequal recombination event that involves strand breaks in the CMT1A-REP sequences [14] . This model implicates a crossing-over distally from the 6.0-kb &oRI fragment on the first chromosome (Fig. 2a) or at a site in the 6.0-kb sequence [14] . Such a cross-over generates a CMT1A chromosome with two copies of this 6.0-kb fragment and an HNPP chromosome lacking this fragment.
As a result, CMT1A patients have a 2:3 ratio of their 7.8-and 6.0-kb fragments, and HNPP patients have a 2:1 ratio. This is probably the site of recombination in the majority of the CMT1A/I-INPP mutations, given the 88% concordance between the RFLP results and the dosage differences in our patients. Similar results were found in a French study [15] for a different collection of subjects, in which all 27 deleted HNPP patients (100%) had a 2:1 ratio of the 7.8-and 6.0-kb fragments. The 12% of our results that were unexpected (discordant) might be explained by the occurrence of recombinations involving other sequences.
We should distinguish between recombinations that occur in the CMT1A-REP sequence but at a different site, and recombinations that probably involve sequences other than the CMT1A-REP sequence. First, a recombination event can occur in the repeat sequence but proximally to the 6.0-kb fragment (Fig. 2b) of the first chromosome.
The result of such a crossover is the production of a CMT1A chromosome with two copies of the 7.8-kb fragment and one copy of the 6.0-kb fragment. The reciprocal product generates an HNPP chromosome with only one 6.0-kb fragment. The involvement of these crossing-over sites gives inverse density ratios when compared with the first mechanism shown in Fig. 2a . The different products obtained in Fig. 2a and 2b could result from the same initiation process of recombination but might include branch migration and subsequent nicking of the heteroduplex structures at different sites. In any case, recombination in CMT1A-REP sequences is responsible for the majority of mutations in our CMT1A/HNPP patients (96%). Second, recombination can probably occur in sequences other than the CMT lA-REP sequence.
This mechanism is
suggested when we compare the results of the RFLP and the repeat-probe in patient LY273, for whom RFLP probe analysis demonstrates a partial deletion. This deletion involves the PMP22 gene but not the more distally located pVAW4 12 and pEW4Ol loci. A model for such a recombination is proposed in Fig. 2c and involves the recombination of a sequence between the PMP22 gene and the pEW4Ol/pVAW412 loci on the first chromosome and a sequence proximal to the PMP22 gene on the second chromosome.
The result of such a mechanism is an unchanged, equal dosage ratio for the 7.8/6.0-kb fragments. Still other sequences can probably recombine to produce a normal 7.8/6.0-kb dosage ratio but show deleted alleles by the RFLP probes. For HNPP patient LY506, a recombination could have occurred in a sequence between the pEW4O1/pVAW412 loci and the distal CMT lA-REP sequence on the first chromosome and in a sequence between the proximal CMT1A-REP and the PMP22 gene on the second chromosome (Fig. 2d) . Also, the LY326 result could be the product of a recombination between PMP22 and pEW4O1/pVAW412 on the first chromosome and a sequence proximal to the CMTIA-REP sequence carrying the 7.8-kb EcoRI fragment of the second chromosome (Fig. 2e) . The latter series of proposed recombination sites can be confirmed by finding the reciprocal recombination products and by gathering additional sequence and physical mapping data from the regions supposedly involved.
The mutations in LY273 and LY326 involve a partial deletion and a partial duplication.
Partial duplications have been described [2 1-24] and seem to be underestimated common products of recombinations mediated by as yet uncharacterized sequences in the l'lpll.2-pl2 region.
In conclusion, CMTIA-REP sequences are involved in almost all duplications and deletions in CMT1A and HNPP. This junction fragments [25] . Here, using a 1.8-kb EcoRI fragment of the CMTIA-REP repeat sequence as a probe and subsequent comparison of &oRE fragment hybridization densities, we found that a majority of these patients show a breakpoint distally to the 6.0-kb fragment of the first chromosome.
In a few patients, this breakpoint is located proximally to the 6.0-kb fragment. One analysis gave a false negative with respect to a deletion, one partial deletion did not alter ratios of c20G2, and one partial duplication gave ratios expected to correspond to HNPP. 
